Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ..
BACKGROUND: Accurate antibody tests are essential to monitor the SARS-CoV-2 pandemic. Lateral flow immunoassays (LFIAs) can deliver testing at scale. However, reported performance varies, and sensitivity analyses have generally been conducted on serum from hospitalised patients. For use in community testing, evaluation of finger-prick self-tests, in non-hospitalised individuals, is required.
METHODS: Sensitivity analysis was conducted on 276 non-hospitalised participants. All had tested positive for SARS-CoV-2 by reverse transcription PCR and were ≥21 days from symptom onset. In phase I, we evaluated five LFIAs in clinic (with finger prick) and laboratory (with blood and sera) in comparison to (1) PCR-confirmed infection and (2) presence of SARS-CoV-2 antibodies on two 'in-house' ELISAs. Specificity analysis was performed on 500 prepandemic sera. In phase II, six additional LFIAs were assessed with serum.
FINDINGS: 95% (95% CI 92.2% to 97.3%) of the infected cohort had detectable antibodies on at least one ELISA. LFIA sensitivity was variable, but significantly inferior to ELISA in 8 out of 11 assessed. Of LFIAs assessed in both clinic and laboratory, finger-prick self-test sensitivity varied from 21% to 92% versus PCR-confirmed cases and from 22% to 96% versus composite ELISA positives. Concordance between finger-prick and serum testing was at best moderate (kappa 0.56) and, at worst, slight (kappa 0.13). All LFIAs had high specificity (97.2%-99.8%).
INTERPRETATION: LFIA sensitivity and sample concordance is variable, highlighting the importance of evaluations in setting of intended use. This rigorous approach to LFIA evaluation identified a test with high specificity (98.6% (95%CI 97.1% to 99.4%)), moderate sensitivity (84.4% with finger prick (95% CI 70.5% to 93.5%)) and moderate concordance, suitable for seroprevalence surveys.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Thorax - 75(2020), 12 vom: 01. Dez., Seite 1082-1088 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Flower, Barnaby [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 08.12.2020 Date Revised 29.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/thoraxjnl-2020-215732 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31370774X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31370774X | ||
| 003 | DE-627 | ||
| 005 | 20231225151142.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/thoraxjnl-2020-215732 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1045.xml |
| 035 | |a (DE-627)NLM31370774X | ||
| 035 | |a (NLM)32796119 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Flower, Barnaby |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.12.2020 | ||
| 500 | |a Date Revised 29.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a BACKGROUND: Accurate antibody tests are essential to monitor the SARS-CoV-2 pandemic. Lateral flow immunoassays (LFIAs) can deliver testing at scale. However, reported performance varies, and sensitivity analyses have generally been conducted on serum from hospitalised patients. For use in community testing, evaluation of finger-prick self-tests, in non-hospitalised individuals, is required | ||
| 520 | |a METHODS: Sensitivity analysis was conducted on 276 non-hospitalised participants. All had tested positive for SARS-CoV-2 by reverse transcription PCR and were ≥21 days from symptom onset. In phase I, we evaluated five LFIAs in clinic (with finger prick) and laboratory (with blood and sera) in comparison to (1) PCR-confirmed infection and (2) presence of SARS-CoV-2 antibodies on two 'in-house' ELISAs. Specificity analysis was performed on 500 prepandemic sera. In phase II, six additional LFIAs were assessed with serum | ||
| 520 | |a FINDINGS: 95% (95% CI 92.2% to 97.3%) of the infected cohort had detectable antibodies on at least one ELISA. LFIA sensitivity was variable, but significantly inferior to ELISA in 8 out of 11 assessed. Of LFIAs assessed in both clinic and laboratory, finger-prick self-test sensitivity varied from 21% to 92% versus PCR-confirmed cases and from 22% to 96% versus composite ELISA positives. Concordance between finger-prick and serum testing was at best moderate (kappa 0.56) and, at worst, slight (kappa 0.13). All LFIAs had high specificity (97.2%-99.8%) | ||
| 520 | |a INTERPRETATION: LFIA sensitivity and sample concordance is variable, highlighting the importance of evaluations in setting of intended use. This rigorous approach to LFIA evaluation identified a test with high specificity (98.6% (95%CI 97.1% to 99.4%)), moderate sensitivity (84.4% with finger prick (95% CI 70.5% to 93.5%)) and moderate concordance, suitable for seroprevalence surveys | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a clinical epidemiology | |
| 650 | 4 | |a respiratory infection | |
| 650 | 4 | |a viral infection | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 700 | 1 | |a Brown, Jonathan C |e verfasserin |4 aut | |
| 700 | 1 | |a Simmons, Bryony |e verfasserin |4 aut | |
| 700 | 1 | |a Moshe, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Frise, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Penn, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Kugathasan, Ruthiran |e verfasserin |4 aut | |
| 700 | 1 | |a Petersen, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Daunt, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Ashby, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Riley, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Atchison, Christina Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Graham P |e verfasserin |4 aut | |
| 700 | 1 | |a Satkunarajah, Sutha |e verfasserin |4 aut | |
| 700 | 1 | |a Naar, Lenny |e verfasserin |4 aut | |
| 700 | 1 | |a Klaber, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Badhan, Anjna |e verfasserin |4 aut | |
| 700 | 1 | |a Rosadas, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Sureda-Vives, Macià |e verfasserin |4 aut | |
| 700 | 1 | |a Cheeseman, Hannah M |e verfasserin |4 aut | |
| 700 | 1 | |a O'Hara, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Fontana, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Pallett, Scott J C |e verfasserin |4 aut | |
| 700 | 1 | |a Rayment, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Rachael |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Luke S P |e verfasserin |4 aut | |
| 700 | 1 | |a McClure, Myra O |e verfasserin |4 aut | |
| 700 | 1 | |a Cherepanov, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Tedder, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Ashrafian, Hutan |e verfasserin |4 aut | |
| 700 | 1 | |a Shattock, Robin |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Darzi, Ara |e verfasserin |4 aut | |
| 700 | 1 | |a Elliot, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Barclay, Wendy S |e verfasserin |4 aut | |
| 700 | 1 | |a Cooke, Graham S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thorax |d 1946 |g 75(2020), 12 vom: 01. Dez., Seite 1082-1088 |w (DE-627)NLM00010387X |x 1468-3296 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2020 |g number:12 |g day:01 |g month:12 |g pages:1082-1088 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/thoraxjnl-2020-215732 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2020 |e 12 |b 01 |c 12 |h 1082-1088 | ||